HRP20181459T1 - Humanizirani antagonisti anti-beta7 i njihove uporabe - Google Patents

Humanizirani antagonisti anti-beta7 i njihove uporabe

Info

Publication number
HRP20181459T1
HRP20181459T1 HRP20181459TT HRP20181459T HRP20181459T1 HR P20181459 T1 HRP20181459 T1 HR P20181459T1 HR P20181459T T HRP20181459T T HR P20181459TT HR P20181459 T HRP20181459 T HR P20181459T HR P20181459 T1 HRP20181459 T1 HR P20181459T1
Authority
HR
Croatia
Prior art keywords
thererfor
humanized anti
beta7 antagonists
beta7
antagonists
Prior art date
Application number
HRP20181459TT
Other languages
English (en)
Inventor
Mark S. Dennis
Sherman Fong
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HRP20181459T1 publication Critical patent/HRP20181459T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HRP20181459TT 2004-09-03 2018-09-12 Humanizirani antagonisti anti-beta7 i njihove uporabe HRP20181459T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60737704P 2004-09-03 2004-09-03
EP15185749.7A EP2990422B1 (en) 2004-09-03 2005-09-02 Humanized anti-beta7 antagonists and uses therefor

Publications (1)

Publication Number Publication Date
HRP20181459T1 true HRP20181459T1 (hr) 2018-10-19

Family

ID=36000753

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20120171T HRP20120171T1 (hr) 2004-09-03 2012-02-21 Humanizirani anti-beta 7 antagonisti i njihove uporabe
HRP20160034TT HRP20160034T1 (hr) 2004-09-03 2016-01-13 Humanizirani antagonisti anti-beta7 i njihove uporabe
HRP20181459TT HRP20181459T1 (hr) 2004-09-03 2018-09-12 Humanizirani antagonisti anti-beta7 i njihove uporabe

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HR20120171T HRP20120171T1 (hr) 2004-09-03 2012-02-21 Humanizirani anti-beta 7 antagonisti i njihove uporabe
HRP20160034TT HRP20160034T1 (hr) 2004-09-03 2016-01-13 Humanizirani antagonisti anti-beta7 i njihove uporabe

Country Status (27)

Country Link
US (10) US7528236B2 (hr)
EP (4) EP2322556B1 (hr)
JP (2) JP5062887B2 (hr)
KR (2) KR101433494B1 (hr)
CN (3) CN103304667B (hr)
AT (1) ATE534668T1 (hr)
AU (1) AU2005279720B2 (hr)
BR (1) BRPI0515602B1 (hr)
CA (1) CA2577678C (hr)
CY (2) CY1112277T1 (hr)
DK (4) DK1784426T3 (hr)
ES (4) ES2690079T3 (hr)
HK (5) HK1112002A1 (hr)
HR (3) HRP20120171T1 (hr)
HU (3) HUE028441T2 (hr)
IL (3) IL181473A (hr)
LT (2) LT2990422T (hr)
MX (3) MX341370B (hr)
NO (3) NO341308B1 (hr)
NZ (2) NZ553328A (hr)
PL (4) PL3530673T3 (hr)
PT (3) PT2990422T (hr)
RS (3) RS57636B1 (hr)
RU (1) RU2453558C2 (hr)
SI (4) SI1784426T1 (hr)
WO (1) WO2006026759A2 (hr)
ZA (1) ZA200701575B (hr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200515915A (en) * 2002-11-08 2005-05-16 Wackvom Ltd Extract of Trapa natans and methods of using the same
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
RS57636B1 (sr) * 2004-09-03 2018-11-30 Genentech Inc Humanizovani anti-beta7 antagonisti i njihova upotreba
AU2005306399B2 (en) * 2004-11-19 2012-02-09 Biogen Ma Inc. Treatment for multiple sclerosis
US10982250B2 (en) * 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
US7875431B2 (en) 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
CA2683568A1 (en) * 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
MX2010007515A (es) 2008-01-11 2010-11-12 Chemo Sero Therapeut Res Inst Anticuerpo antiintegrina a9 humana humanizado mejorado.
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP6219556B2 (ja) * 2008-05-16 2017-10-25 ジェネンテック， インコーポレイテッド ベータ７インテグリンアンタゴニストを用いた消化管炎症性障害の治療評価のためのバイオマーカーの使用
CA2726087A1 (en) * 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
RU2010153578A (ru) * 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
RU2011104348A (ru) * 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AU2010236257A1 (en) * 2009-04-17 2011-11-03 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
US8399625B1 (en) * 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120208208A1 (en) * 2009-10-30 2012-08-16 Ni Yan G Pcsk9 immunoassay
AU2011221229B2 (en) * 2010-02-23 2015-06-18 F. Hoffmann-La Roche Ag Anti-angiogenesis therapy for the treatment of ovarian cancer
EP2558122A4 (en) * 2010-04-15 2014-03-05 Vegenics Pty Ltd COMBINATION TREATMENT WITH VEGF-C ANTAGONISTS
SG10201502967RA (en) 2010-04-16 2015-05-28 Biogen Ma Inc Anti-vla-4 antibodies
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2816803A1 (en) * 2010-11-02 2012-05-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CA2831732C (en) * 2011-03-31 2019-12-31 Genentech, Inc. Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
US20150010563A1 (en) * 2012-02-21 2015-01-08 Massachusetts Eye & Ear Infirmary Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
PT2825558T (pt) 2012-03-13 2019-07-11 Hoffmann La Roche Terapêutica combinada para o tratamento do cancro do ovário
KR101732552B1 (ko) 2012-08-22 2017-05-08 재단법인 목암생명과학연구소 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
RU2015145610A (ru) * 2013-03-27 2017-05-04 Дженентек, Инк. Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
MX2016012282A (es) 2014-03-27 2017-01-06 Genentech Inc Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AU2016222683A1 (en) * 2015-02-26 2017-07-13 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3329276A2 (en) * 2015-07-27 2018-06-06 H. Hoffnabb-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
AU2017234009A1 (en) 2016-03-14 2018-09-27 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
BR112018068625A2 (pt) 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
BR112019022268A2 (pt) 2017-04-28 2020-05-19 Millennium Pharm Inc método para o tratamento de distúrbios pediátricos
CN111417410B (zh) 2017-12-01 2023-06-23 艾伯维公司 糖皮质激素受体激动剂及其免疫缀合物
WO2019200202A1 (en) 2018-04-12 2019-10-17 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
WO2020145669A1 (ko) * 2019-01-10 2020-07-16 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
US20220259291A1 (en) * 2019-06-10 2022-08-18 Takeda Pharmaceutical Company Limited Antibody purification methods and compositions thereof
UY38926A (es) 2019-10-16 2021-05-31 Morphic Therapeutic Inc INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA
IL300133A (en) 2020-07-31 2023-03-01 Genentech Inc Anti-integrin antibody compositions in cell 7 and devices
WO2023086910A1 (en) 2021-11-12 2023-05-19 Genentech, Inc. Methods of treating crohn's disease using integrin beta7 antagonists

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4308428A (en) * 1979-12-26 1981-12-29 Cbs Inc. System for electronically simulating radiation effects produced by a rotary loudspeaker
US4331348A (en) * 1980-01-09 1982-05-25 Raidel John E Vehicle suspension
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
DK0605522T3 (da) * 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
MX9706049A (es) * 1995-02-10 1998-02-28 Leukosite Inc Adresinas vasculares mucosas y sus usos.
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
WO2000030681A1 (en) 1998-11-25 2000-06-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
AU2390400A (en) * 1999-01-08 2000-07-24 Brigham And Women's Hospital Methods and compositions for modulating cytokine release by alphaebeta7-expressing cells
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
JP4257210B2 (ja) * 2002-02-06 2009-04-22 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ パーソナルケア装置及び冷却装置を有するパーソナルケアシステム
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
SV2006001990A (es) 2004-01-09 2006-01-30 Pfizer Anticuerpos contra madcam
EP2168986A3 (en) * 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
RS57636B1 (sr) 2004-09-03 2018-11-30 Genentech Inc Humanizovani anti-beta7 antagonisti i njihova upotreba
US10982250B2 (en) 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
JP2007302676A (ja) 2007-05-29 2007-11-22 Genentech Inc ヒト化抗β７アンタゴニストおよびその使用

Also Published As

Publication number Publication date
NZ585628A (en) 2012-01-12
WO2006026759A2 (en) 2006-03-09
RU2453558C2 (ru) 2012-06-20
CN101094868A (zh) 2007-12-26
WO2006026759A3 (en) 2006-10-05
EP1784426A2 (en) 2007-05-16
IL181473A0 (en) 2007-07-04
PT2322556E (pt) 2016-02-15
EP2990422A1 (en) 2016-03-02
SI3530673T1 (sl) 2022-08-31
US20080025971A1 (en) 2008-01-31
DK2322556T3 (en) 2016-01-25
PL1784426T3 (pl) 2012-04-30
US20200048354A1 (en) 2020-02-13
KR20120115587A (ko) 2012-10-18
JP5062887B2 (ja) 2012-10-31
ZA200701575B (en) 2008-09-25
CA2577678A1 (en) 2006-03-09
PL2990422T3 (pl) 2018-11-30
NO342491B1 (no) 2018-06-04
EP2990422B1 (en) 2018-07-11
US8835133B2 (en) 2014-09-16
MX337423B (es) 2016-03-04
SI1784426T1 (sl) 2012-03-30
KR101364276B1 (ko) 2014-02-20
JP2012107050A (ja) 2012-06-07
HK1210977A1 (en) 2016-05-13
NO20171287A1 (no) 2007-06-01
SI2990422T1 (sl) 2018-10-30
IL181473A (en) 2013-07-31
HK1188798A1 (en) 2014-05-16
DK2990422T3 (en) 2018-09-17
MX2007002675A (es) 2007-06-11
SI2322556T1 (sl) 2016-02-29
AU2005279720A1 (en) 2006-03-09
BRPI0515602A (pt) 2008-07-29
US20120208984A1 (en) 2012-08-16
CN104710532A (zh) 2015-06-17
EP3530673A1 (en) 2019-08-28
CA2577678C (en) 2014-12-02
US20090226437A1 (en) 2009-09-10
HK1221473A1 (zh) 2017-06-02
NO341308B1 (no) 2017-10-02
PL3530673T3 (pl) 2022-08-01
HUE028441T2 (hu) 2016-12-28
LT3530673T (lt) 2022-06-10
NO20071740L (no) 2007-06-01
DK1784426T3 (da) 2012-03-12
US20060093601A1 (en) 2006-05-04
NO342319B1 (no) 2018-05-07
HRP20120171T1 (hr) 2012-03-31
CN104710532B (zh) 2019-01-18
US8779100B2 (en) 2014-07-15
WO2006026759A9 (en) 2006-05-18
EP2322556B1 (en) 2015-10-21
US7528236B2 (en) 2009-05-05
RU2007112102A (ru) 2008-10-10
ES2690079T3 (es) 2018-11-19
US20170044261A1 (en) 2017-02-16
AU2005279720B2 (en) 2011-07-28
ES2911482T3 (es) 2022-05-19
KR20070050986A (ko) 2007-05-16
HRP20160034T1 (hr) 2016-02-12
LT2990422T (lt) 2018-10-10
RS54409B1 (en) 2016-04-28
DK3530673T3 (da) 2022-04-19
ES2555355T3 (es) 2015-12-30
EP2322556A1 (en) 2011-05-18
RS57636B1 (sr) 2018-11-30
ATE534668T1 (de) 2011-12-15
MX341370B (es) 2016-08-17
CY1112277T1 (el) 2015-12-09
PT2990422T (pt) 2018-10-18
NZ553328A (en) 2010-06-25
PL2322556T3 (pl) 2016-04-29
HK1156955A1 (zh) 2012-06-22
ES2377979T3 (es) 2012-04-03
IL244803B (en) 2018-02-28
HK1112002A1 (en) 2008-08-22
US20150197560A1 (en) 2015-07-16
IL226717A (en) 2016-04-21
HUE058817T2 (hu) 2022-09-28
CN103304667B (zh) 2015-04-08
JP5255135B2 (ja) 2013-08-07
US8124082B2 (en) 2012-02-28
JP2008512382A (ja) 2008-04-24
RS52213B (en) 2012-10-31
CN103304667A (zh) 2013-09-18
HUE039591T2 (hu) 2019-01-28
CY1117124T1 (el) 2017-04-05
US20170210807A1 (en) 2017-07-27
EP1784426B1 (en) 2011-11-23
US20130288302A1 (en) 2013-10-31
NO20171288A1 (no) 2007-06-01
CN101094868B (zh) 2013-07-10
US20180291104A1 (en) 2018-10-11
EP3530673B1 (en) 2022-03-30
US7687605B2 (en) 2010-03-30
IL244803A0 (en) 2016-04-21
BRPI0515602B1 (pt) 2021-08-17
KR101433494B1 (ko) 2014-08-22
IL226717A0 (en) 2013-07-31
PT1784426E (pt) 2012-03-06

Similar Documents

Publication Publication Date Title
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
IL245462A0 (en) Antagonists of human origin against cmet